Docket No.: PIR-88501
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`John C. Byrd, et al.
`
`Application No.: 14/523,650
`
`Confirmation No.: 1095
`
`Filed: October 24, 2014
`
`Art Unit: 1629
`
`For: METHODS OF TREATING AND
`PREVENTING GRAFT VERSUS HOST
`DISEASE
`
`Examiner: TRAN, My Chau T.
`
`AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
`
`Dear Sir:
`
`In response to the pending Final Office Action, dated November 3, 2016, in connection with
`
`the above-referenced application, Applicant submits this Amendment and Response. Please amend
`
`the application as follows.
`
`Amendments to the Claims begin on page 2.
`
`Remarks begin on page 8.
`
`B4628250.5
`
`
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`John C. Byrd, et al.
`
`Application No.: 14/523,650
`
`Confirmation No.: 1095
`
`Filed: October 24, 2014
`
`Art Unit: 1629
`
`For: METHODS OF TREATING AND
`PREVENTING GRAFT VERSUS HOST
`DISEASE
`
`Examiner: TRAN, My Chau T.
`
`AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
`
`Dear Sir:
`
`In response to the pending Final Office Action, dated November 3, 2016, in connection with
`
`the above-referenced application, Applicant submits this Amendment and Response. Please amend
`
`the application as follows.
`
`Amendments to the Claims begin on page 2.
`
`Remarks begin on page 8.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`IN THE CLAIMS:
`
`1-20. (Canceled)
`
`2
`
`Docket No.: PIR-88501
`
`21.
`
`(Currently Amended) A method of treating chronic graft versus host disease
`
`(GVHD) comprising administering to a patient having chronic GVHD a therapeutically effective
`
`amount of a compound of the structure:
`
`a-0
`
`or a pharmaceutically acceptable salt thereof
`
`thereby treating the chronic GVHD in the patient.
`
`22.
`
`(Previously Presented) The method of claim 21, wherein the patient has classic
`
`chronic GVHD.
`
`23.
`
`(Previously Presented) The method of claim 21, wherein the patient has overlap
`
`chronic GVHD.
`
`24.
`
`(Previously Presented) The method of claim 21, wherein the patient has steroid-
`
`dependent/refractory chronic GVHD.
`
`25.
`
`(Previously Presented) The method of claim 21, wherein the therapeutically effective
`
`amount of the compound is about 40 mg/day, about 140 mg/day, about 280 mg/day, about
`
`420 mg/day, about 560 mg/day, or about 840 mg/day.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`3
`
`Docket No.: PIR-88501
`
`26.
`
`(New) The method of claim 21, wherein, following administration of the compound,
`
`the patient achieves partial response (PR), wherein the PR is an objective response in one involved
`
`organ in the patient with no evidence of progression elsewhere and no requirements for additional
`
`systemic therapy.
`
`27.
`
`(New) The method of claim 21, wherein, following administration of the compound,
`
`the patient achieves complete response (CR), wherein the CR is a complete restoration of symptoms
`
`attributable to GVHD.
`
`28.
`
`(New) The method of claim 21, wherein, following administration of the compound,
`
`the severity of the GVHD is reduced.
`
`29.
`
`(New) The method of claim 21, wherein the patient has chronic lymphocytic
`
`leukemia (CLL ).
`
`30.
`
`(New) The method of claim 21, wherein the patient had a hematopoietic cell
`
`transplantation.
`
`31.
`
`(New) The method of claim 21, wherein the chronic GVHD is sclerodermatous
`
`GVHD, steroid resistant GVHD, cyclosporin-resistant GVHD, refractory GVHD, oral GVHD,
`
`reticular oral GVHD, erosive GVHD, or ulcerative oral GVHD.
`
`32.
`
`(New) The method of claim 21, wherein the chronic GVHD is sclerodermatous
`
`GVHD.
`
`33.
`
`(New) The method of claim 21, wherein the chronic GVHD is steroid resistant
`
`GVHD.
`
`34.
`
`(New) The method of claim 21, wherein the chronic GVHD is cyclosporin-resistant
`
`GVHD.
`
`35.
`
`36.
`
`37.
`
`38.
`
`B4628250.5
`
`(New) The method of claim 21, wherein the chronic GVHD is refractory GVHD.
`
`(New) The method of claim 21, wherein the chronic GVHD is oral GVHD.
`
`(New) The method of claim 21, wherein the chronic GVHD is reticular oral GVHD.
`
`(New) The method of claim 21, wherein the chronic GVHD is erosive GVHD.
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`4
`
`Docket No.: PIR-88501
`
`39.
`
`(New) The method of claim 21, wherein the chronic GVHD is ulcerative oral
`
`GVHD.
`
`40.
`
`(New) The method of claim 21, wherein about 420 mg/day of the compound is
`
`administered.
`
`41.
`
`(New) The method of claim 21, wherein about 420 mg of the compound is
`
`administered once per day.
`
`42.
`
`43.
`
`(New) The method of claim 21, wherein the compound is administered orally.
`
`(New) The method of claim 21, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`44.
`
`(New) The method of claim 21, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`45.
`
`(New) The method of claim 24, wherein about 420 mg/day of the compound is
`
`administered.
`
`46.
`
`(New) The method of claim 24, wherein about 420 mg of the compound is
`
`administered once per day.
`
`47.
`
`(New) The method of claim 24, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`48.
`
`(New) The method of claim 24, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`49.
`
`(New) The method of claim 24, wherein, following administration of the compound,
`
`the patient achieves partial response (PR), wherein the PR is an objective response in one involved
`
`organ in the patient with no evidence of progression elsewhere and no requirements for additional
`
`systemic therapy.
`
`50.
`
`(New) The method of claim 24, wherein, following administration of the compound,
`
`the patient achieves complete response (CR), wherein the CR is a complete restoration of symptoms
`
`attributable to GVHD.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`5
`
`Docket No.: PIR-88501
`
`51.
`
`(New) The method of claim 24, wherein, following administration of the compound,
`
`the severity of the GVHD is reduced.
`
`52.
`
`(New) The method of claim 26, wherein about 420 mg/day of the compound is
`
`administered.
`
`53.
`
`(New) The method of claim 26, wherein about 420 mg of the compound is
`
`administered once per day.
`
`54.
`
`(New) The method of claim 26, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`55.
`
`(New) The method of claim 26, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`56.
`
`(New) The method of claim 27, wherein about 420 mg/day of the compound is
`
`administered.
`
`57.
`
`(New) The method of claim 27, wherein about 420 mg of the compound is
`
`administered once per day.
`
`58.
`
`(New) The method of claim 27, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`59.
`
`(New) The method of claim 27, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`60.
`
`(New) The method of claim 33, wherein about 420 mg/day of the compound is
`
`administered.
`
`61.
`
`(New) The method of claim 33, wherein about 420 mg of the compound is
`
`administered once per day.
`
`62.
`
`(New) The method of claim 33, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`63.
`
`(New) The method of claim 33, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`6
`
`Docket No.: PIR-88501
`
`64.
`
`(New) The method of claim 33, wherein, following administration of the compound,
`
`the patient achieves partial response (PR), wherein the PR is an objective response in one involved
`
`organ in the patient with no evidence of progression elsewhere and no requirements for additional
`
`systemic therapy.
`
`65.
`
`(New) The method of claim 33, wherein, following administration of the compound,
`
`the patient achieves complete response (CR), wherein the CR is a complete restoration of symptoms
`
`attributable to GVHD.
`
`66.
`
`(New) The method of claim 33, wherein, following administration of the compound,
`
`the severity of the GVHD is reduced.
`
`67.
`
`(New) The method of claim 35, wherein about 420 mg/day of the compound is
`
`administered.
`
`68.
`
`(New) The method of claim 35, wherein about 420 mg of the compound is
`
`administered once per day.
`
`69.
`
`(New) The method of claim 35, wherein about 420 mg/day of the compound is
`
`administered orally.
`
`70.
`
`(New) The method of claim 35, wherein about 420 mg of the compound is
`
`administered orally once per day.
`
`71.
`
`(New) The method of claim 35, wherein, following administration of the compound,
`
`the patient achieves partial response (PR), wherein the PR is an objective response in one involved
`
`organ in the patient with no evidence of progression elsewhere and no requirements for additional
`
`systemic therapy.
`
`72.
`
`(New) The method of claim 35, wherein, following administration of the compound,
`
`the patient achieves complete response (CR), wherein the CR is a complete restoration of symptoms
`
`attributable to GVHD.
`
`73.
`
`(New) The method of claim 35, wherein, following administration of the compound,
`
`the severity of the GVHD is reduced.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`7
`
`Docket No.: PIR-88501
`
`74.
`
`(New) A method of treating chronic graft versus host disease (GVHD) comprising
`
`administering to a patient having chronic GVHD from 140 mg/day to 840 mg/day of a compound of
`
`the structure:
`
`75.
`
`(New) A method of treating chronic graft versus host disease (GVHD) comprising
`
`administering to a patient having chronic GVHD about 420 mg/day of a compound of the structure:
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`8
`
`Docket No.: PIR-88501
`
`Remarks
`
`Claims 1, 3-11, 15, 16, and 18-25 were pending, of which claims 19 and 20 were withdrawn.
`
`By this Amendment, claims 1, 3-11, 15, 16, and 18-20 have been canceled without prejudice, claim
`
`21 has been amended, and new claims 26-75 have been added. Support for the claim amendments
`
`and new claims may be found throughout the specification and claims as originally filed. No new
`
`matter has been added.
`
`For example, support for new claims 26, 27, 49, 50, 64, 65, 71, and 72 may be found at least
`
`in paragraphs [00247] and [00248] of the specification as originally filed.
`
`Support for new claims 29 and 30 may be found in previous claims 10 and 11, which have
`
`been canceled.
`
`Claims 31-39 are based on previous claims 7-9, which have been canceled.
`
`Amendment or cancellation of claims should in no way be construed as an acquiescence to a
`
`rejection, or surrender of any subject matter. Applicant reserves the option to prosecute the
`
`originally filed claims, or similar ones, in the instant or subsequently filed patent applications.
`
`Interview Summary
`
`Applicant thanks the Examiner for extending the courtesy of an Examiner Interview
`
`conducted on December 8, 2016, in order to discuss the outstanding rejections of record. As
`
`discussed, the only remaining rejections in this case are provisional nonstatutory double patenting
`
`rejections over later-filed applications.
`
`Response to Claim Obiections
`
`The Office objects to claims 7-11 and 22-24 because they depend from a rejected base
`
`claim. Furthermore, Applicant thanks the Examiner for her indication that the subject matter of
`
`claims 7-11 and 22-24 would be allowable if rewritten in independent form. In response, Applicant
`
`requests that the Examiner consider the arguments submitted herewith as they are believed to
`
`overcome all of the pending rejections. Incidentally, while claims 7-11 have been canceled, new
`
`claims 29-39 recite the features of previous claims 7-11.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`9
`
`Docket No.: PIR-88501
`
`Response to Reiections based on the Judicially Created Doctrine of
`
`Obviousness-Type Double Patenting
`
`Claims 1, 3-6, 15, 16, 18, 21, and 25 stand rejected on the grounds of nonstatutory
`
`obviousness-type double patenting as allegedly being unpatentable over claims 1-5, 16, 17, 19, 21,
`
`and 22 of U.S. Patent Appl. No. 14/558,297 (Blazar) filed on December 2, 2014.
`
`Claims 1, 3-6, 15, 16, 18, 21, and 25 stand rejected on the grounds of nonstatutory
`
`obviousness-type double patenting as allegedly being unpatentable over claims 1, 48, and 49 of U.S.
`
`Patent Appl. No. 15/060,010 (Chong) filed on March 3, 2016.
`
`MPEP § 804(I)(B)(l) states "If a 'provisional' nonstatutory obviousness-type double
`
`patenting (ODP) rejection is the only rejection remaining in the earlier filed of the two pending
`
`applications, while the later-filed application is rejectable on other grounds, the examiner should
`
`withdraw that rejection and permit the earlier-filed application to issue as a patent without a
`
`terminal disclaimer." Importantly, the MPEP further clarifies the meaning of "earlier-filed": "Where
`
`at least one of the two applications is entitled to the benefit of a U.S. nonprovisional application
`
`under 35 U.S.C. 120, 121, or 365(c), the "earlier-filed" application is the one having the earliest date
`
`to which it is entitled benefit under 35 U.S.C. 120, 121, and/or 365(c)." (MPEP 1490(VI)(D)).
`
`By these terms, the subject application is the earlier-filed application with respect to both
`
`Blazar and Chong. Since this provisional obviousness-type double patenting (ODP) rejection is the
`
`only remaining rejection in this application, Applicants request that the ODP rejection should be
`
`withdrawn, and the subject application should be passed to allowance.
`
`B4628250.5
`
`
`
`Application No. 14/523,650
`Amendment and Response
`
`Docket No.: PIR-88501
`
`Conclusion
`
`The Applicant believes that the fees due in connection with the filing of this paper have been
`
`paid. Nevertheless, the Director is hereby authorized to charge any and all required fees to our
`
`Deposit Account No. 06-1448, reference PIR-885.01. If a telephone conversation with Applicant's
`
`Attorney would expedite prosecution of the application, the Examiner is urged to contact the
`
`undersigned.
`
`Dated: April 27, 2017
`
`Respectfully submitted,
`
`By: /Hathaway P. Russell/
`Hathaway P. Russell
`Registration No.: 46,488
`FOLEY HOAG LLP
`155 Seaport Blvd
`Boston, Massachusetts 02210
`(617) 832-1000
`Attorney For Applicant
`
`B4628250.5
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
